Conatus names executive VP, clinical development
This article was originally published in Scrip
Conatus Pharmaceuticals, a biotechnology company focused on the development and commercialization of medicines to treat liver disease, has named Dr David T Hagerty executive vice-president of clinical development. He will oversee the company's medical activities including clinical development, clinical operations, regulatory affairs, biostatistics, quality assurance and drug safety. Dr Hagerty has been an independent consultant in clinical development since April 2013. Prior to this he was senior vice-president and chief medical officer at Ardea Biosciences.